Skip to main content
Premium Trial:

Request an Annual Quote

MolecularWare Embarks on Next Stage of Growth with $2.5M in Funding


While funding may be hard to come by in some high-tech sectors, bioinformatics companies seem to be bucking the economic trend. Last week, MolecularWare of Cambridge, Mass., closed on a $2.5 million first round of financing from several funding sources, led by the Aspen Investment Group and KnowledgeCube Group.

MolecularWare joins Viaken, Inpharmatica, and Scimagix, who secured a total of $82 million in funds during July.

Richard Kivel, CEO of MolecularWare, said the company would put the money toward new hires and continued development of its DigitalGenome data management software. He said the company would also look into building a second suite of software products that will address data mining and storage.

DigitalGenome automatically captures data from various high-throughput instruments, such as liquid handling robots, microarraying robots, and microarray scanners. There are currently three stages to the system: experimental design, analysis, and integration. Kivel said the company is hoping to expand the current functionality of the system based on user feedback. “We have to stay ahead of the curve,” he said. “Some startup is out there trying to build a better product somewhere.”

The company expects to increase its current staff of 10 to 15 through new hires in technology development and sales. Long term, Kivel said, he sees MolecularWare gaining more of an international presence.

MolecularWare’s current customers for DigitalGenome include the Whitehead Institute at MIT, and Riken University for Genome Research and the University of Tsukuba in Japan.

— BT

Filed under

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.